BidaskClub Lowers Integra Lifesciences (NASDAQ:IART) to Strong Sell

Integra Lifesciences (NASDAQ:IART) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Friday, January 5th.

A number of other research analysts have also weighed in on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $52.00 price objective on shares of Integra Lifesciences in a report on Friday, January 5th. UBS Group lowered Integra Lifesciences to a “market perform” rating in a report on Tuesday, January 2nd. Raymond James Financial reissued a “market perform” rating and issued a $55.00 target price on shares of Integra Lifesciences in a report on Tuesday, January 2nd. Bank of America lowered Integra Lifesciences from a “buy” rating to a “neutral” rating in a report on Tuesday, January 2nd. Finally, Zacks Investment Research raised Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Tuesday, December 26th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. Integra Lifesciences presently has an average rating of “Hold” and a consensus price target of $52.70.

Integra Lifesciences (IART) traded up $0.10 during trading on Friday, hitting $50.57. The stock had a trading volume of 352,700 shares, compared to its average volume of 677,656. Integra Lifesciences has a twelve month low of $40.51 and a twelve month high of $56.42. The stock has a market capitalization of $3,968.60, a PE ratio of 82.90, a PEG ratio of 1.63 and a beta of 0.65. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.47 by ($0.02). Integra Lifesciences had a return on equity of 16.35% and a net margin of 4.52%. The business had revenue of $278.83 million for the quarter, compared to analyst estimates of $286.00 million. During the same period in the prior year, the company earned $0.93 EPS. The company’s revenue was up 11.4% on a year-over-year basis. sell-side analysts expect that Integra Lifesciences will post 1.85 EPS for the current fiscal year.

In related news, Director Barbara B. Hill bought 10,768 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The shares were acquired at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the acquisition, the director now owns 55,540 shares in the company, valued at approximately $2,591,496.40. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Richard D. Gorelick sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the sale, the vice president now owns 21,665 shares in the company, valued at $1,022,371.35. The disclosure for this sale can be found here. Company insiders own 21.50% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Acrospire Investment Management LLC grew its stake in Integra Lifesciences by 280.0% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after purchasing an additional 1,400 shares in the last quarter. Riverhead Capital Management LLC grew its stake in Integra Lifesciences by 49.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after purchasing an additional 799 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Integra Lifesciences by 8.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after purchasing an additional 218 shares in the last quarter. Whittier Trust Co. acquired a new stake in Integra Lifesciences during the 3rd quarter valued at approximately $169,000. Finally, San Francisco Sentry Investment Group CA acquired a new stake in Integra Lifesciences during the 2nd quarter valued at approximately $174,000. Hedge funds and other institutional investors own 87.58% of the company’s stock.

WARNING: This piece of content was reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/integra-lifesciences-iart-rating-lowered-to-strong-sell-at-bidaskclub/1820880.html.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.